Clear Street Group Inc. Takes $1.04 Million Position in Kenvue Inc. $KVUE

Clear Street Group Inc. purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 60,000 shares of the company’s stock, valued at approximately $1,035,000.

Several other large investors have also bought and sold shares of KVUE. Elyxium Wealth LLC bought a new position in Kenvue in the fourth quarter valued at approximately $26,000. Physician Wealth Advisors Inc. boosted its stake in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares during the last quarter. SBI Securities Co. Ltd. boosted its stake in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after acquiring an additional 1,027 shares during the last quarter. Leonteq Securities AG bought a new position in Kenvue in the fourth quarter valued at approximately $45,000. Finally, Quarry LP bought a new position in Kenvue in the fourth quarter valued at approximately $76,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.59% of the stock is currently owned by insiders.

Kenvue Trading Down 0.1%

Shares of NYSE:KVUE opened at $18.13 on Monday. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $22.87. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The company’s fifty day simple moving average is $17.43 and its 200 day simple moving average is $17.54. The firm has a market cap of $34.80 billion, a price-to-earnings ratio of 21.32, a PEG ratio of 1.38 and a beta of 0.54.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same period last year, the business posted $0.24 earnings per share. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. As a group, research analysts forecast that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is presently 97.65%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on KVUE shares. Citigroup reduced their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Barclays reduced their price objective on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Weiss Ratings lowered shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. Finally, Argus upgraded shares of Kenvue to a “hold” rating in a report on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.